XHKG1521
Market cap448mUSD
Dec 27, Last price
1.71HKD
1D
0.59%
1Q
128.00%
IPO
-48.02%
Name
Frontage Holdings Corp
Chart & Performance
Profile
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
Income | ||||||||
Revenues | 259,855 3.79% | 250,360 35.74% | 184,441 46.60% | |||||
Cost of revenue | 240,228 | 216,206 | 158,364 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 19,627 | 34,154 | 26,077 | |||||
NOPBT Margin | 7.55% | 13.64% | 14.14% | |||||
Operating Taxes | 3,849 | 10,196 | 6,144 | |||||
Tax Rate | 19.61% | 29.85% | 23.56% | |||||
NOPAT | 15,778 | 23,958 | 19,933 | |||||
Net income | 10,808 -58.00% | 25,735 39.65% | 18,428 7.45% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (2,890) | (7,190) | 2,252 | |||||
BB yield | 0.06% | 0.12% | -0.03% | |||||
Debt | ||||||||
Debt current | 31,809 | 24,243 | 7,300 | |||||
Long-term debt | 176,949 | 104,461 | 108,389 | |||||
Deferred revenue | 2,061 | 2,123 | ||||||
Other long-term liabilities | (12,982) | 18,018 | ||||||
Net debt | 144,043 | 29,454 | (39,928) | |||||
Cash flow | ||||||||
Cash from operating activities | 39,740 | 62,442 | 44,549 | |||||
CAPEX | (21,137) | (47,665) | (50,380) | |||||
Cash from investing activities | (87,626) | (147,910) | (107,443) | |||||
Cash from financing activities | 12,910 | 30,659 | (5,544) | |||||
FCF | 2,255 | (20,433) | (42,803) | |||||
Balance | ||||||||
Cash | 54,598 | 90,520 | 148,707 | |||||
Long term investments | 10,117 | 8,730 | 6,910 | |||||
Excess cash | 51,722 | 86,732 | 146,395 | |||||
Stockholders' equity | 119,457 | 111,339 | 95,932 | |||||
Invested Capital | 440,583 | 378,334 | 298,197 | |||||
ROIC | 3.85% | 7.08% | 7.00% | |||||
ROCE | 3.89% | 7.18% | 6.43% | |||||
EV | ||||||||
Common stock shares outstanding | 2,069,710 | 2,084,432 | 2,115,688 | |||||
Price | 2.32 -20.00% | 2.90 -26.58% | 3.95 -6.40% | |||||
Market cap | 4,801,728 -20.57% | 6,044,853 -27.67% | 8,356,966 -4.73% | |||||
EV | 4,948,415 | 6,077,076 | 8,320,280 | |||||
EBITDA | 55,201 | 63,593 | 49,569 | |||||
EV/EBITDA | 89.64 | 95.56 | 167.85 | |||||
Interest | 7,072 | 3,948 | 2,579 | |||||
Interest/NOPBT | 36.03% | 11.56% | 9.89% |